NIH Institute / Center · HL (NHLBI)
National Heart Lung and Blood Institute
579 funded awards, $384.5M total, FY2023-FY2025.
NIH SBIR/STTR funding decisions are made by Institutes and Centers based on portfolio priorities, NOFO scope, and program officer judgment. Historical funding patterns do not guarantee future funding.
Technology areas funded by NHLBI
Limitations
- RePORTER includes funded projects only, not unfunded applications.
- Panel sidebar reflects panels that have appeared on funded records, not future assignment.
- FOA-route status reflects verification at the timestamp shown.
Pattern read
NHLBI funded 579 records / $385M, with a broad portfolio across heart, lung, blood, and sleep applications. The mix runs heavy on research tools, small-molecule therapeutics for cardiopulmonary disease, medical devices, and health-services platforms (cardiac rehab, hypertension management). Median award is $554K. Concentration is low at 3.8%, one of the most diffuse SBIR-funder portfolios. R44 (301) dominates over R43 (157); STTR participation (R41 at 66) is meaningful. Cardiopulmonary indication clarity has been the most reliable signal in funded work.